Repeated medicine shortages reveal weaknesses in Australian supply chains

An analysis of Australian medicine-shortage records has found that more than half of 40 medicines classed as critically short in an October 2026 dataset had been in shortage before. More than 420 shortages across all impact categories were recorded from late September to early October. These are dated dataset figures, not a newly checked live count for November 13.

A critical rating means a shortage could have life-threatening or serious effects and there may be insufficient alternatives on the Australian market. Each entry can relate to a particular strength or formulation, rather than every version of a medicine. Repeated shortages of long-acting penicillin and pancreatic enzyme treatments were among the examples examined.

Manufacturing problems, raw-material constraints and shifts in demand can interrupt supplies. Clinicians may manage shortages with available alternatives, approved overseas products or other arrangements, but patients can face extra appointments, higher costs and time spent contacting pharmacies. A past shortage does not by itself predict how severe the next one will be.

The Therapeutic Goods Administration says it works with suppliers and health departments but cannot compel a private company to register, manufacture or continue selling a medicine in Australia. Patients should ask their pharmacist or prescriber about their own supply and should not stop, substitute or change a dose on the basis of this general report. The photograph shows illustrative medicine packs, not products certified to be unavailable.